Results from a Randomized Study of Celgene's REVLIMID and Rituximab in Patients with Recurrent Follicular Lymphoma Presented at ASCO

Celgene International Sàrl, a subsidiary of Celgene Corporation

, announced Saturday results from a randomized study comparing REVLIMID (lenalidomide) plus rituximab to lenalidomide monotherapy in previously treated patients with recurrent follicular lymphoma. These data were presented at the 48th American Society of Clinical Oncology Annual Meeting in Chicago, Ill. Follicular lymphoma is the most common indolent non-Hodgkin's lymphoma and the second most common form of non-Hodgkin's lymphomas. Of the 89 evaluable patients, the objective response rates were 73% for patients receiving combination therapy, with 36% achieving a complete response, compared to 51% for patients receiving the lenalidomide monotherapy, with 13% achieving a complete response. With a median follow-up of 1.7 years (range 0.1 – 4.1 years), the median event-free survival for patients in the combination arm was 2 years (p=0.0063), while patients in the lenalidomide monotherapy arm achieved a median EFS of 1.2 years.